Medical News

RSS

Bristol-Myers Squibb, Oncolys complete license agreement for festinavir

Bristol-Myers Squibb Company and Oncolys BioPharma Inc., a privately held biotechnology company based in Japan, announced today that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire exclusive worldwide rights to manufacture, develop and commercialize festinavir, a once-a-day, orally available nucleoside reverse transcriptase inhibitor (NRTI) in Phase II development for HIV.

20 Dec 2010

Health overhaul roundup: Analyzing the individual mandate, watching the politics around reform

While last week's biggest news focused on the court action surrounding the health law, some reports now analyze the controversial provision at the heart of these cases and what the future could look like if it did or did not survive. But reform news also translates into political news, as PolitiFact pinpoints its "Lie of the Year" and the Atlanta Journal Constitution reports on how federal reforms could influence the state's gubernatorial election.

20 Dec 2010

Opsens unveils EasyWire for growth market of Fractional Flow Reserve for coronary lesion assessment

Opsens Inc. today unveiled the EasyWire, developed by its medical division for the growth market of Fractional Flow Reserve for coronary lesion assessment.

20 Dec 2010

Spartan RX CYP2C19 DNA testing system receives European CE Mark certification

Spartan Bioscience Inc., a privately held molecular diagnostics company that develops, manufactures, and markets DNA testing systems for on-demand applications, today announced its Spartan RX CYP2C19 received a CE IVD Mark under the European Directive on In Vitro Diagnostic Medical Devices. The CE Mark certification allows commercial distribution in Europe as well as in all countries recognizing the CE Mark in the Middle East, Africa, Latin America, and Asia-Pacific regions.

20 Dec 2010

Rexahn granted Japanese patent for preclinical compound RX-0047

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it was awarded patent 4,546,454 entitled, "Antisense Oligonucleotides that Inhibit Expression of HIF-1," by the Japanese Patent Office.

20 Dec 2010

Oncothyreon commences combination PX-866/cetuximab Phase 1/2 trial in cancers

Oncothyreon Inc. today announced enrollment of the first patient in a Phase 1/2 trial of PX-866 in combination with the chimeric monoclonal antibody cetuximab (Erbitux®). PX-866 is a small molecule compound designed to inhibit the activity of phosphatidylinositol-3-kinase (PI-3K), a component of an important cell survival signaling pathway.

20 Dec 2010

Itamar Medical, Roche enter development agreement for EndoPAT device

Itamar Medical, the leader in non-invasive vascular health diagnostics, announced today that an agreement has been signed with Roche by which Itamar will develop an EndoPAT device designated for use with animal models, enabling pre-clinical studies examining the efficacy of various compounds in the early stage of drug development essential for later stage development in humans.

20 Dec 2010

Idera reports positive data from IMO-2125/ribavirin combination Phase 1 trial in null-responder HCV patients

Idera Pharmaceuticals, Inc. announced today preliminary data from a 4-week dose-ranging Phase 1 clinical trial of IMO-2125 in combination with ribavirin in 60 treatment-naïve patients with genotype 1 chronic hepatitis C virus (HCV) infection. In the trial, treatment with IMO-2125 in combination with ribavirin was well tolerated and achieved substantial decline in virus levels at two days after the first dose of IMO-2125 and after four weeks of treatment.

20 Dec 2010

Gilead to acquire Arresto

Gilead Sciences, Inc. and Arresto Biosciences, Inc., a privately-held, development-stage biotechnology company focused on medicines to treat fibrotic diseases and cancer, today announced the signing of a definitive agreement pursuant to which Gilead will acquire Arresto. Under the terms of the agreement, Gilead will acquire Arresto for $225 million and potential future payments based on achievement of certain sales levels.

20 Dec 2010

Fibrocell Science submits response to FDA CR letter for azficel-T BLA

Fibrocell Science, Inc., a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that it has submitted its complete response to the Complete Response (CR) letter issued by the U.S. Food & Drug Administration (FDA) regarding the Company's Biologics License Application (BLA) for azficel-T, proposed brand name laViv®, for the treatment of moderate to severe nasolabial folds and wrinkles.

20 Dec 2010

OXIS International files patent application to strengthen Ergothioneine intellectual property portfolio

OXIS International, Inc., today announced that is has filed a patent application titled "Methods and Compositions Using Ergothioneine to Treat a Variety of Health Related Factors" with the U.S. Patent and Trademark Office (USPTO).

20 Dec 2010

Spectrum Pharmaceuticals to be traded on NASDAQ Global Select Market

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, announced today that effective January 3, 2011, it will begin trading on the NASDAQ Global Select Market. The NASDAQ Global Select Market is the highest NASDAQ listing tier based on financial and liquidity criteria. Prior to the effectiveness of this change in the New Year, shares of Spectrum Pharmaceuticals will continue to be traded on the NASDAQ Global Market.

20 Dec 2010

NanoLogix enters collaboration with Advanced Medical German Company of Kuwait

NanoLogix, an innovator in the accelerated detection and identification of microorganisms, is pleased to announce its collaboration with Advanced Medical German Company of Kuwait (AMGKWT). This alliance will support NanoLogix's market penetration goals for the Middle East, North and East Africa with the international marketing focus of Advanced Medical German Company stretching from the Middle East through Africa.

20 Dec 2010

ResCare shareholders approve share exchange transaction with Onex

ResCare, Inc. announced today that its shareholders have approved the share exchange through which an entity sponsored by Onex Partners III, L.P. ("Onex"), an affiliate of Onex Corporation, will complete the acquisition of all of ResCare's stock not currently held by Onex and its affiliates under the terms of the previously announced share exchange agreement between Onex and ResCare.

20 Dec 2010

Aeterna Zentaris reaches agreement with FDA for Solorel SPA as a diagnostic test in AGHD

Aeterna Zentaris Inc. today announced that it has reached agreement with the Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for Solorel® (AEZS-130, macimorelin) which will enable the Company to complete the ongoing registration study required to gain approval as a diagnostic test for Adult Growth Hormone Deficiency (AGHD).

20 Dec 2010

EMA grants SME designation to PROLOR Biotech

PROLOR Biotech, Inc.,, a clinical stage company developing next generation biobetter therapeutic proteins, today announced that the European Commission and the European Medicines Agency (EMA) has granted PROLOR the designation of "Small and Medium Sized Enterprise" (SME).

20 Dec 2010

King submits ACUROX NDA to FDA

King Pharmaceuticals®, Inc. and Acura Pharmaceuticals, Inc. today announced that King has submitted a New Drug Application (NDA) for ACUROX® (oxycodone HCl) Tablets to the U.S. Food and Drug Administration (FDA), including a request for priority review classification. ACUROX® is an immediate release tablet containing oxycodone HCl intended for the relief of moderate to severe pain.

20 Dec 2010

First Edition: December 20, 2010

Today's headlines include more analysis on the continuing legal challenges to the health law and the path they might take to the Supreme Court.

20 Dec 2010

Arrowhead launches new company, Ablaris to commercialize novel weight loss technology

Arrowhead Research Corporation today announced that it has executed an exclusive world-wide license on technology developed by Drs. Wadih Arap and Renata Pasqualini at MD Anderson Cancer Center for use in weight loss and obesity-related metabolic conditions, and that it has launched a new company, Ablaris Therapeutics Inc., to commercialize this platform.

20 Dec 2010

Icagen, Pfizer commence Nav1.7 Phase I clinical studies for pain and related disorders

Icagen, Inc. today provided an update on its sodium channel program for pain and related disorders, which is being conducted in collaboration with Pfizer. As previously reported, the companies recently selected a candidate compound to advance into further clinical studies. Dosing of this candidate compound has now been initiated in a Phase I study in healthy volunteers.

20 Dec 2010

Medical News

Bristol-Myers Squibb, Oncolys complete license agreement for festinavir

Health overhaul roundup: Analyzing the individual mandate, watching the politics around reform

Opsens unveils EasyWire for growth market of Fractional Flow Reserve for coronary lesion assessment

Spartan RX CYP2C19 DNA testing system receives European CE Mark certification

Rexahn granted Japanese patent for preclinical compound RX-0047

Oncothyreon commences combination PX-866/cetuximab Phase 1/2 trial in cancers

Itamar Medical, Roche enter development agreement for EndoPAT device

Idera reports positive data from IMO-2125/ribavirin combination Phase 1 trial in null-responder HCV patients

Gilead to acquire Arresto

Fibrocell Science submits response to FDA CR letter for azficel-T BLA

OXIS International files patent application to strengthen Ergothioneine intellectual property portfolio

Spectrum Pharmaceuticals to be traded on NASDAQ Global Select Market

NanoLogix enters collaboration with Advanced Medical German Company of Kuwait

ResCare shareholders approve share exchange transaction with Onex

Aeterna Zentaris reaches agreement with FDA for Solorel SPA as a diagnostic test in AGHD

EMA grants SME designation to PROLOR Biotech

King submits ACUROX NDA to FDA

First Edition: December 20, 2010

Arrowhead launches new company, Ablaris to commercialize novel weight loss technology

Icagen, Pfizer commence Nav1.7 Phase I clinical studies for pain and related disorders

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News